U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232810) titled 'Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer' on Nov. 13.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 mon...